Core Insights - Orchestra BioMed is presenting data on Atrioventricular Interval Modulation (AVIM) Therapy, highlighting its potential to transform the management of hypertensive heart disease at the Georgia Innovation Summit on October 10, 2025 [1][2] - AVIM Therapy is recognized as a novel, device-based approach that could redefine standards of care for hypertension, which is a major contributor to heart failure [2][4] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through strategic partnerships with leading medical device companies [3] - The company's primary product candidate is AVIM Therapy, aimed at treating hypertension, the leading risk factor for mortality globally [3][6] AVIM Therapy Details - AVIM Therapy is designed to work with standard dual-chamber pacemakers to significantly lower blood pressure and has shown promising results in pilot studies [8] - The MODERATO I and II pilot studies demonstrated substantial reductions in 24-hour ambulatory systolic blood pressure, with reductions of 11.6 mmHg and 15.6 mmHg at one day, respectively [5] - Long-term follow-up indicates sustained blood pressure reduction and improvements in cardiac function, with no significant adverse effects on heart metrics [5][8] Strategic Collaborations - Orchestra BioMed has a strategic partnership with Medtronic to develop and commercialize AVIM Therapy for patients with uncontrolled hypertension who are indicated for a pacemaker, targeting an estimated global population of over 750,000 patients annually [4][6] - The therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in patients at increased cardiovascular risk, representing a U.S. population of over 7.7 million patients [4][8]